@article{cdd472aa2e9d4a519b2f60b52dc67b0e,
title = "Tubal flushing with oil-based or water-based contrast at hysterosalpingography for infertility: long-term reproductive outcomes of a randomized trial",
abstract = "Objective: To determine the impact of oil -based versus water -based contrast on pregnancy and live birth rates < 5 years after hysterosalpingography (HSG) in infertile women. Design: A 5 -year follow-up study of a multicenter randomized trial. Setting: Hospitals. Patient(s): Infertile women with an ovulatory cycle, 18 - 39 years of age, and having a low risk of tubal pathology. Intervention(s): Use of oil -based versus water -based contrast during HSG. Main Outcome Measure(s): Ongoing pregnancy, live births, time to ongoing pregnancy, second ongoing pregnancy. Result(s): A total of 1,119 women were randomly assigned to HSG with oil -based contrast (n = 557) or water -based contrast (n = 562). After 5 years, 444 of 555 women in the oil group (80.0\%) and 419 of 559 women in the water group (75.0\%) had an ongoing pregnancy (relative risk [RR] 1.07; 95\% con fi dence interval [CI] 1.00 - 1.14), and 415 of 555 women in the oil group (74.8\%) and 376 of 559 women in the water group (67.3\%) had live births (RR 1.11; 95\% CI 1.03 - 1.20). In the oil group, 228 pregnancies (41.1\%) were conceived naturally versus 194 (34.7\%) pregnancies in the water group (RR 1.18; 95\% CI 1.02 - 1.38). The time to ongoing pregnancy was signi fi cantly shorter in the oil group versus the water group (10.0 vs. 13.7 months; hazard ratio, 1.25; 95\% CI 1.09 - 1.43). No difference was found in the occurrence of a second ongoing pregnancy. Conclusion(s): During a 5 -year time frame, ongoing pregnancy and live birth rates are higher after tubal fl ushing with oil -based contrast during HSG compared with water -based contrast. More pregnancies are naturally conceived and time to ongoing pregnancy is shorter after HSG with oil -based contrast. Clinical Trial Registration Number: Netherlands Trial Register (NTR) 3270 and NTR6577(www.trialregister.nl). (Fertil Steril (R) 2020;114:155-62. (C) 2020 by American Society for Reproductive Medicine.)",
keywords = "female infertility, hysterosalpingography, media, oil-based contrast medium, ongoing pregnancy, water-based contrast medium, Female infertility, MEDIA",
author = "\{van Rijswijk\}, J. and \{van Welie\}, N. and K. Dreyer and C.T. Pham and H.R. Verhoeve and A. Hoek and \{de Bruin\}, J.P. and A.W. Nap and \{van Hooff\}, M.H.A. and M. Goddijn and A.B. Hooker and P. Bourdrez and \{van Dongen\}, A.J.C.M. and \{van Rooij\}, I.A.J. and \{van Rijnsaardt-Lukassen\}, H.G.M. and \{van Golde\}, R.J.T. and \{van Heteren\}, C.F. and M.J. Pelinck and A.E.J. Duijn and M. Kaplan and C.B. Lambalk and V. Mijatovic and B.W.J. Mol",
note = "Funding Information: The H2Oil study (NTR 3270) was an investigator-initiated study that was funded by the two academic institutions (Amsterdam Medical Center and Vrije Universiteit Medical C entre) of the Amsterdam UMC, the Netherlands. The follow-up study (NTR 6577) was also an investigator-initiated study with funding by Guerbet, France. The funders had no role in thestudy design, collection, analysis and interpretation of the data. Funding Information: J.v.R. has nothing to disclose. N.v.W. has nothing to disclose. K.D. reports travel and speakers fees from Guerbet. C.T.P. reports financial support from Guerbet, France, outside the submitted work. H.R.V. reports consultancy fees from Ferring. A.H. declares that the Department of Obstetrics and Gynaecology, University Medical Centre Groningen, received an unrestricted research grant from Ferring Pharmaceuticals BV, the Netherlands. J.P.d.B. reports personal fees from Ferring Medical Advisory Board, grants from Ferring B.V., grants from Merck Serono B.V., outside the submitted work. A.W.N. has nothing to disclose. M.H.A.v.H. has nothing to disclose. M.G. has nothing to disclose. A.B.H. has nothing to disclose. P.B. has nothing to disclose. A.J.C.M.v.D. has nothing to disclose. I.A.J.v.R. is on the Advisory Board of Ferring on follitropin delta. H.G.M.v.R.-L. has nothing to disclose. R.J.T.v.G. has nothing to disclose. C.F.v.H. has nothing to disclose. M.J.P. has nothing to disclose. A.E.J.D. has nothing to disclose. M.K. has nothing to disclose. C.B.L. reports speaker{\textquoteright}s fee from Ferring in the past, and his department receives research grants from Ferring, Merck, and Guerbet. V.M. reports receiving travel and speaker fees, as well as research grants from Guerbet. B.W.J.M. is supported by a NHMRC Practitioner Fellowship (GNT1082548) and reports consultancy for ObsEva, Merck Merck KGaA, and Guerbet. Publisher Copyright: {\textcopyright} 2020 American Society for Reproductive Medicine",
year = "2020",
month = jul,
day = "1",
doi = "10.1016/j.fertnstert.2020.03.022",
language = "English",
volume = "114",
pages = "155--162",
journal = "Fertility and Sterility",
issn = "0015-0282",
publisher = "Elsevier Inc.",
number = "1",
}